A5063440222- Parathyroid Disorders and Treatments
- Alkaline Phosphatase Research Studies
- Vitamin D Research Studies
- Bone health and osteoporosis research
- Dialysis and Renal Disease Management
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Bone and Joint Diseases
- Bone health and treatments
- Vaccine Coverage and Hesitancy
- Genetic Syndromes and Imprinting
- Pharmacological Effects and Toxicity Studies
- Chronic Kidney Disease and Diabetes
- COVID-19 and healthcare impacts
- Genetic and Kidney Cyst Diseases
- Pancreatitis Pathology and Treatment
- Biochemical and Molecular Research
- Biomedical Research and Pathophysiology
- Peptidase Inhibition and Analysis
- Heparin-Induced Thrombocytopenia and Thrombosis
- Folate and B Vitamins Research
- Renal and Vascular Pathologies
- Central Venous Catheters and Hemodialysis
- Renal Transplantation Outcomes and Treatments
- Rheumatoid Arthritis Research and Therapies
Karolinska University Hospital
2016-2025
Karolinska Institutet
2016-2025
Mertiva (Sweden)
2024
Baxter (Sweden)
2016-2023
Malmö University
2023
Université de Strasbourg
2023
University of Birmingham
2023
University of Glasgow
2023
RELX Group (United States)
2020
International Society of Nephrology
2020
ABSTRACT Mineral and bone disorders (MBD) are common in patients with chronic kidney disease (CKD), contributing to significant morbidity mortality. For several decades, the first-line approach controlling hyperparathyroidism CKD was by exogenous calcium loading. Since turn of millennium, however, a growing awareness vascular calcification risk has led paradigm shift management move away from calcium-based phosphate binders. As consequence, contemporary may be at negative balance, which,...
Renal osteodystrophy (ROD) is a heterogeneous group of metabolic bone diseases complicating progressive chronic kidney disease (CKD). Bone biomarkers and imaging techniques may help to assess health predict fractures in CKD but do have important inherent limitations. By informing on turnover mineralization, biopsy guide prevention treatment ROD its consequences. According recent survey conducted among European nephrologists, biopsies are performed rather exceptionally, both for clinical...
Klotho, a multifunctional protein, acts as co-receptor in fibroblast growth factor 23 and exerts its impact through various molecular pathways, including Wnt, hypoxia-inducible insulin-like 1 pathways. The physiological significance of Klotho is the regulation vitamin D phosphate metabolism well serving vital component aging neurodegeneration. role neurodegeneration particular has gained considerable attention. In this narrative review we highlight several key insights into basis function...
Bone strength is determined not only by bone quantity [bone mineral density (BMD)] but also quality, including matrix composition, collagen fiber arrangement, microarchitecture, geometry, mineralization, and turnover, among others. These aspects influence elasticity, the load-bearing repair capacity of bone, microcrack propagation are thus key to fractures their avoidance. In chronic kidney disease (CKD)-associated osteoporosis, factors traditionally associated with a lower mass (advanced...
Abstract Mineral and bone disorder (MBD) is widely prevalent in children with chronic kidney disease (CKD) associated significant morbidity. CKD may cause disturbances remodelling/modelling, which are more pronounced the growing skeleton, manifesting as short stature, pain deformities, fractures, slipped epiphyses ectopic calcifications. Although assessment of health a key element clinical care CKD, it remains major challenge for physicians. On one hand, biopsy histomorphometry gold standard...
<b><i>Background/Aims:</i></b> The association between serum alkaline phosphatase (ALP) with adverse cardiovascular outcomes, in Chronic Kidney Disease (CKD) patients has previously been reported and may be a result of increased vascular calcification inflammation. Here we report, for the first time, effects pharmacologic epigenetic modulation on levels ALP kidney function via novel oral small molecule BET inhibitor, apabetalone, CKD patients....
In patients with cardiovascular disease, considerable residual risk remains despite evidence-based secondary prevention measures. Alkaline phosphatase (ALP) has been suggested as a modifiable factor. We sought to determine whether reduction by the bromodomain and extra-terminal (BET) protein inhibitor apabetalone is associated concomitant lowering of serum ALP.In post-hoc analysis 795 established coronary heart disease statin treatment, who participated in phase 2 placebo-controlled trials...
Experiences from the first wave of 2019 coronavirus disease (COVID-19) pandemic can aid in development future preventive strategies. To date, risk prediction models for COVID-19-related incidence and outcomes hemodialysis (HD) patients are missing.We developed COVID-19 mortality among HD patients. We studied 38 256 a multi-national dialysis cohort between 3 March July 2020. Risk were validated, based on predictors readily available outpatient units. compared with without COVID-19, matched...
After the reports of severe adverse reactions to AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose vaccine were recommended a second Pfizer's BNT162b2 vaccine. In hemodialysis patients, we compared humoral immunogenicity and tolerability homologous vaccination with ChAdOx1-nCoV-19/ChAdOx1-nCoV-19 (ChAd/ChAd) BNT162b2/BNT162b2 (BNT/BNT) heterologous first ChAdOx1-nCoV-19 (ChAd/BNT). multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels,...
ABSTRACT Background Chronic kidney disease mineral bone disorder (CKD-MBD) is a condition characterized by alterations of calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23) metabolism that in turn promote disorders, vascular calcifications, increase cardiovascular (CV) risk. Nephrologists’ awareness diagnostic, prognostic, therapeutic tools to manage CKD-MBD plays primary role adequately preventing managing this clinical practice. Methods A national...
Patients with chronic kidney disease (CKD) experience a several-fold increased risk of fracture. Despite the high incidence and associated excess morbidity premature mortality, bone fragility in CKD, or CKD-associated osteoporosis, remains blind spot nephrology an immense treatment gap. Defining phenotype is prerequisite for appropriate therapy osteoporosis at patient level. In present review, we suggest 10 practical 'tips tricks' assessment health patients CKD. We describe clinical,...